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Abstract
Background
Anemia is one of the most impactful nutrient deficiencies in the world and disproportionately
affects children in low-resource settings. Point-of-care devices (PoCDs) measuring blood
hemoglobin (Hb) are widely used in such settings to screen for anemia due to their low cost,
speed, and convenience. Here we present the first iteration of Aptus, a new PoCD which
measures Hb and hematocrit (HCT).
Aim
To evaluate the accuracy of Aptus and HemoCue® Hb 301 against an automated hematol-
ogy analyzer (Medonic®) in Gambian children aged 6–35 months and the Aptus’ usage in
the field.
Methods
Aptus, HemoCue® and Medonic® were compared using venous blood (n = 180), and Aptus
and HemoCue® additionally using capillary blood (n = 506). Agreement was estimated
using Bland-Altman analysis and Lin’s concordance. Usage was assessed by error occur-
rence and user experience.
Results
Mean Hb values in venous blood did not significantly differ between Aptus and HemoCue®
(10.44±1.05 vs 10.56±0.93g/dl, p>0.05), but both measured higher Hb concentrations than
Medonic® (9.75±0.99g/dl, p<0.0001). Lin’s coefficient between Aptus and Medonic® was rc
= 0.548, between HemoCue® and Medonic® rc = 0.636. Mean bias between the PoCDs
venous measurements was -0.11g/dl with limits of agreement (LoA) -1.63 and 1.40g/dl. The
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bias was larger for the comparisons between the Medonic® and both Aptus (0.69g/dl, LoA
0.92 and 2.31g/dl) and HemoCue® (0.81g/dl, LoA 0.17 and 1.78g/dl). ROC curves showed
an AUC of 0.933 in HemoCue® and 0.799 in Aptus. Capillary Hb was higher with Aptus than
HemoCue® (10.33±1.11g/dl vs 10.01±1.07g/dl, p<0.0001). Mean bias was 0.32g/dl with
LoA of -1.91 and 2.54g/dl. Aptus‘ usage proved intuitive, yet time-to-results and cuvettes
could be improved.
Conclusion
Both PoCDs showed a relatively limited bias but large LoA. Aptus and HemoCue® showed
similar accuracy, while both overestimated Hb levels. Aptus showed promise, with its opera-
tion unimpaired by field conditions as well as being able to show HCT values.
Introduction
Anemia is one of the most prevalent nutrient deficiencies worldwide. The most recent data
from the World Health Organization (WHO) in 2011 estimate that the prevalence of anemia
in children under the age of five is 42.6% worldwide, with the highest prevalence in the African
region at 62.3% [1]. The most prominent causative factor is iron deficiency anemia (IDA),
which has been shown to have detrimental immediate and long-term impact on growth, organ
function and cognitive development in children [1–4]. IDA is estimated to affect 1.24 billion
people worldwide, leading to 35 million disability-adjusted life years (DALYs) and contribut-
ing the largest share to total years lived with disability (YLD) [1, 5, 6]. The standard measure-
ment to determine anemia status occurs via blood hemoglobin (Hb) levels, which enables
quantitative but not causative assessment of anemia [1, 7]. As iron deficiency, defined in
young children as inflammation-adjusted ferritin concentration < 12μg/L, is more costly and
technologically sophisticated to measure, IDA is commonly assumed to represent 50% of ane-
mia in a given area when lacking data on iron status [5]. However, anemia can be caused by
other factors such as infections, other micronutrient deficiencies or hemoglobinopathies [5].
As such, implementing tests to screen for the cause of anemia can prevent misdiagnosis and
consequently mistreatment. One approach is to measure the ratio of Hb to hematocrit (HCT),
referred to as the mean corpuscular Hb concentration (MCHC), which decreases in microcytic
anemias such as IDA [8, 9].
Furthermore, HCT is often used to approximate Hb in low-resource and field settings
where direct Hb measurement is not possible or feasible. The correlation of HCT with Hb is,
however, not sufficiently consistent [9]. Therefore, measuring HCT and Hb together would
provide a more refined and robust procedure for anemia diagnostics suitable to low-resource
settings. To this end, point-of-care devices (PoCDs) that are affordable, durable and easy to
use are required. Presently, the most commonly used PoCD, set as the standard device in the
guidelines for Demographic and Health Surveys (DHS) [10], is the HemoCue1 series, which
requires a simple fingerprick and provides results seen as comparable to automatic hematology
analyzers [11, 12]. However, it solely measures Hb.
Aptus device
The Aptus is a novel PoCD certified in accordance with the requirements of the EU Directive
for in vitro diagnostics medical devices (directive 98/79/EC) and provides Hb and HCT
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measurements simultaneously via centrifugation and photometry. More portable than the
HemoCue1Hb 301, Aptus is a handheld device that could improve the in-field diagnosis of
anemia in low- and middle-income countries (LMICs). The Aptus model used here was one of
the first available commercially. Data from the NHS Healthcare Trust at Imperial College,
London, showed good correlation with the Sysmex1 bioanalyzer [13]. However, evidence to
support its use in rural community-based studies in LMICs or with children is not yet
available.
HemoCue1 device
The HemoCue1 has been extensively evaluated and is seen as the standard PoCD for this type
of setting [10]. However, as the results on its accuracy are mixed, its status as standard device
is not undisputed [11, 14–19]. For HemoCue1Hb301, only one other study has been con-
ducted in young children in rural low-resource settings [14].
Aims
This paper presents the first comparative pilot study of these devices in LMIC field settings in
rural clinics. The study aimed to: (1) compare Hb concentrations measured in venous blood
by HemoCue1Hb 301 and Aptus with a gold standard automated hematology analyzer in
young children with IDA in a rural and remote community in the Upper River Region of The
Gambia; (2) compare the Hb measurements provided by HemoCue1Hb301 and Aptus in
capillary blood; (3) determine the usability of Aptus in these settings and 4) highlight potential
improvements to the Aptus model used here before a wider global launch. This was an ancil-
lary study embedded within the IHAT-GUT clinical trial (Registration Number:
NCT02941081) [20].
Materials and methods
Devices
The specifications of the analytical devices used in this study are summarized in Table 1. The
HemoCue1Hb 301 and Aptus Model 10-100-01 used in this study are both PoCDs that can
measure Hb in either capillary blood, collected from a finger prick, or venous blood, diluted
with appropriate anticoagulants such as EDTA. The Aptus requires a smaller minimum sam-
ple volume of 4–8 μl (Table 1). The HemoCue1 is able to measure also in arterial whole
blood. The HemoCue1 is larger and heavier than the Aptus, and both the cuvette storage and
operating temperatures have a more limited range for HemoCue1. Humidity and altitude
ranges are not quantified by the manufacturer of the HemoCue1. While the Aptus has an
integrated rechargeable battery, the HemoCue1 can be operated either by changeable batter-
ies or with a power outlet. The HemoCue1 has connectivity features allowing collected results
to be read out on a computer, which this Aptus model lacked. Both devices have a built-in self-
test and are calibrated to internationally recognized standards. Because Aptus measures Hb
and HCT simultaneously, it requires an extra centrifugation step and has a measurement time
of 60 seconds. The HemoCue1measures only Hb in 10 seconds. Both devices utilize photom-
etry for their measurements: the Aptus measures three wavelengths and the HemoCue1 two.
Centrifugation requires the Aptus to be placed on a reasonably level surface that is not dis-
turbed by significant movement during sample processing. The Aptus does not directly mea-
sure Hb, as is the case for the HemoCue1. Rather, it measures HCT and MCHC of the
cellular constituents after centrifugation, and calculates Hb by multiplying MCHC with HCT.
Additionally, the Aptus can display results in relation to pre-specified reference ranges. These
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include the WHO and the Dacie and Lewis ranges, which can be corrected for altitude, sex,
pregnancy status and age via the touchscreen [21–23]. The automated hematology analyzer
used as the clinical laboratory gold standard was the Medonic1M-Series M16S/M20S Auto-
loader (hereafter Medonic1).
To assess usability of the Aptus in field settings, a log of error messages as displayed by the
Aptus was kept. These included overfilling or underfilling of cuvettes, termination of centrifu-
gation due to tilt or vibrations of the device, and incorrect cuvette placement. These errors,
combined with the user experience of the single operator of the Aptus in this study, were used
to extrapolate possible improvements for the device in future model versions.
Study setting and participants
This prospective study was conducted between 8 October and 22 November 2018 and was
ancillary to the IHAT-GUT trial conducted in the Basse´ government area, Upper River Region
(URR), The Gambia [20]. The climate is Sahelian, following a pattern of rainy season from
June-October and dry season from November-May [24]. During the study period, average
temperature and humidity around Basse´ were 31˚C with 67% humidity in October, then 29˚C
with 58% humidity in November [25]. The Gambia ranks 174 out of 189 on the Human Devel-
opment Index [26], with the rural URR representing the most socio-economically deprived
region of the country, exhibiting limited access to health services or appropriate infrastructure.
Table 1. Specifications for HemoCue1Hb 301 and Aptus device [21–23].
HemoCue1Hb 301 Aptus
Dimensions 140 × 70 × 160 mm 78 x 83 x 52 mm
Weight 500g (incl. batteries) 96g
Storage temp. Analyzer: 0–50˚C (32–122˚F) Analyzer: 0–50˚C (32–122˚F)
Cuvettes: unopened 10–40˚C (50–104˚F); short-term storage (6 weeks) -18–
50˚C (0–122˚F); 12-month open vial stability
Cuvettes: unopened or opened and resealed 0–50˚C (32–122˚F)
Storage humidity - 0–90%
Operating temp. 10–40˚C (50–104˚F) 5–45˚C (41–113˚F)
Operating
humidity
- 0–90%
Altitude - < 4500m
Power AC adapter (6v) or 4 AA batteries Micro USB (5V) or integrated Li-Ion battery
Interface Printer and HemoCue1 Micro USB
Basic Connect™ including optional barcode scanner
Quality Control Built-in self-test, optional liquid controls Internal quality control. Self-Calibration and self-checks before every
measurement, optional liquid controls
Principle Absorbance measurement of whole blood at an Hb/HbO2 isosbestic point
at 506 nm and 880 nm
Centrifugation and photometry at 515 nm, 660 nm and 940nm
Calibration Factory calibrated against the ICSH method Hb: Factory calibrated against HiCN method. HCT: Microhematocrit
method
Sample Material Capillary, venous (EDTA suitable), arterial whole blood Capillary, venous (EDTA, Heparin suitable)
Sample Volume ~10 μL 4–8 μL
Measurement
Range
0–25.6 g/dL (0–256 g/L, 0–15.9 mmol/L) Hb: 5–25 g/dl
HCT: 0.15–0.75 L/L (15–75%)
Measurement
Time
< 10 seconds 60 seconds
Price Analyzer: ~£400 Analyzer: £250
Consumables: ~£80 per 200 tests Consumables: £60 per 200 tests
https://doi.org/10.1371/journal.pone.0239931.t001
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This was particularly the case for the study area, located in the Wuli and Sandu districts
approximately 400 km inland of the capitol Banjul, on the opposite, northern side of the river
Gambia to Basse´, the only major town in the district [24]. This area is predominantly com-
posed of subsistence farming communities from which the study participants were recruited.
The Basse´ region consistently scores below the national average on most morbidity and mor-
tality measures, with the latest Demographic and Health Survey from 2011 (DHS) listing
under-five mortality rates at 92 per 1000 (1 in 11) and the proportion of stunted children at
32% [24]. Furthermore, 82.5% of children in the Basse´ area meet the WHO criteria for anemia
of Hb< 11.0 g/dl, with 56.4% and 6.5% meeting the criteria for moderate and severe anemia,
respectively [24].
All subjects were evaluated and screened for IHAT-GUT study eligibility. In the present
study, this was a convenience sample of all children enrolled in the IHAT-GUT study and who
attended the study clinics at the pre-specified study timepoints for blood collection. In short,
participants were otherwise healthy children of 6–35 months with IDA at enrollment, defined
as Hb between 7–11 g/dl and serum ferritin below 30 μg/l, from 17 villages in the study area.
Exclusion criteria included severe malnutrition, severe anemia, congenital anomalies and diar-
rhea or dysentery. For a comprehensive list, please refer to the main study protocol [20].
Ethical issues
Ethical approval for this ancillary study to the IHAT-GUT trial [20] was obtained from The
Gambia Government/MRCG Joint Ethics Committee (SCC1632, 3/10/2018). No additional
intervention or participant procedures were necessary for this study. As such, written
informed consent of the parent was obtained for each participant as part of the IHAT-GUT
main trial before the study procedures commenced. All staff participating in recruitment were
trained in GCP, informed consent procedures and translation of the provided information
material into local languages. In case of illiteracy, the trial was explained in understandable
terms in a local language in the presence of an impartial witness in a room with appropriate
privacy. In case of literacy, parents were given sufficient time to read the information material.
Sufficient time was also given to address any questions parents might have. No child took part
in the trial without prior informed consent, and all participants were protected according to
the Sponsor Clinical Trial/Non-Negligent Harm Insurance and Medical Malpractice Insur-
ance. For further information we refer to the IHAT-GUT protocol [20].
Hemoglobin measurements
The IHAT-GUT study protocol defines that on study day 85, venous blood is collected instead
of capillary blood. These samples were used in the present study for the comparisons between
the PoCDs and the automated hematology analyzer. Venipuncture was performed by the
IHAT-GUT study nurses following standardized study protocols. Briefly, the participant’s arm
was wiped with 70% ethanol. A 21-gauge Multifly1 needle was used for venipuncture. The
samples for the Medonic1 analysis were collected in an EDTA Microtainer1 blood collection
tube, which was continuously inverted for 30 seconds immediately after collection, thus far
exceeding the recommended minimum of 10 inversions. Immediately after the blood tubes
were filled, the needle was removed and the blood that remained in the needle and attached
tube systems was drained on a plastic surface to form a large drop, from which both Hemo-
Cue1 and Aptus samples were collected (gravity method). The EDTA tubes were subse-
quently transported to the laboratory site at the MRC field station in Basse´ in an isolated
carrying box containing cooling elements, where they were analyzed with the Medonic1
within four hours of collection.
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For all other study timepoints, participants visited the study clinics weekly for a finger prick
performed by the nurse following standardized study protocol. These capillary blood samples
were used for the comparisons between the two PoCDs, HemoCue1 and Aptus. We note that
the way the finger prick was performed as part of IHAT-GUT differed from what the Aptus man-
ufacturer recommends, i.e. blood was collected from the thumb and slight pressure was applied
for the blood drop to form. Briefly, the child’s thumb was wiped with 70% ethanol and pricked
with a Sherwood Safety blood lancet. A little pressure was applied to the finger so that a domed
drop formed. Capillary blood for both HemoCue1 and Aptus was collected from separate drops
of blood from the same fingerprick to minimize variability due to the collection technique. The
first drop was wiped clean with cotton, the second drop was used for the measurement with the
HemoCue1, and the third drop was used for the Aptus measurement by one of two devices.
HemoCue1measurements were conducted by one IHAT-GUT study nurse, whereas the Aptus
was exclusively operated by the present study lead author. If during screening a measurement
was Hb<7 g/dl (the WHO definition of severe anemia) a venous blood sample was taken and
analyzed with Medonic within four hours. If this confirmed the field measurement, the child was
classified as severely anemic and stopped the study supplementation to receive standard treat-
ment with oral iron syrups, as per Gambian National Guidelines. Therefore, both PoCDs in this
study were evaluated for their usefulness as screening tools, while the analyzer served as diagnos-
tic standard. As such, the WHO standard as cut-off was valid for both PoCDs, which is in line
with manufacturers’ recommendations. Indeterminate screening results, i.e. an Hb�7g/dl, were
thus not analyzed with the reference standard as per the IHAT-GUT protocol [20]. In the present
study, both indeterminate test results and reference standards were used in the comparative anal-
ysis and handled as continuous variables and not categorized based on any Hb threshold.
HemoCue1, Aptus and Medonic1Hb measurements were all performed in accordance
with the manufacturers’ operating manuals. Results were recorded on the devices and then man-
ually in a notebook. The study nurses also collected further clinical information during field
studies as pertaining to the IHAT-GUT study. The nurses, lab staff and the principal investigator
performing the Aptus tests were aware of Hb reference values via their biomedical training.
Quality control (QC)
Before each measurement, the Aptus self-calibrates and self-checks during the centrifugation
phase to account for environmental influences, such as temperature and humidity. The device
is also able to check for underfilling and overfilling, can remove air bubbles by centrifugation,
has an internal QC and displays error messages if it fails.
The HemoCue1 has an internal quality control “self-test”, which the system performs
automatically every time the analyzer is turned on. The test is performed at regular intervals
(typically every two hours) if the analyzer remains switched on. If the self-test fails, an error
code will be displayed. Additionally, the Eurotrol Hb301 external QC (levels 1 and 2) was used
to verify the accuracy of HemoCue1Hb301 devices daily.
For the Medonic1, the external QCs were run at the start of each analysis day. If the QC
results were within range, then the study samples were tested. The laboratory supervisor
approved the QC results daily. For external quality control, the laboratory participates in an
external inter-laboratory proficiency scheme with OneWorld Canada for hematology full blood
analysis and has good clinical laboratory practice (GCLP) accreditation by Qualogy Ltd (UK).
Data analysis
Aptus displayed error messages in 7 out of 190 venous blood measurements (4%) and 108 out
of 615 capillary blood measurements (17.6%) (Fig 1). These were due to under- or over-filling
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of the cuvettes and are expected in such high throughput settings with inexperienced users.
HemoCue1 did not display error messages during this study, irrespective of how well the
cuvettes were filled. Medonic1’s error measurements are repeated in the lab and, therefore,
no further sample measurements had to be excluded from the analysis presented here. Of the
691 valid sample measurements, 183 were collected from venous blood and 508 from capillary
blood (Fig 1).
As this study occurred between study day 57 and 113 of the IHAT-GUT trial, some partici-
pants had developed severe anemia since the beginning of the study (Tables 2 and 3) and were
subsequently discontinued from supplementation in the IHAT-GUT trial to receive standard
treatment. Since this study presents a methodological comparison of the devices, the clinical
consequences of the measurements do not pertain to our results and these low Hb values were
therefore not excluded from our analysis.
Sample size for IHAT-GUT was determined as per the published study protocol [20]. The
present study is an exploratory method comparison pilot study. As such, as there is no avail-
able performance data of Aptus in field settings, no data is available to perform a meaningful
power or sample size calculation.
SPSS Statistics version 25 (IBM corp.) was used for data analysis and visualization. Using
three times IQR as cutoff, three Aptus measurements (15.4g/dl, 18.5g/dl and 20.7g/dl) from
venous blood were considered outliers and removed from further analysis, leaving 180 venous
blood measurements for analysis (Fig 1). Two Aptus Hb measurements (15.9g/dl and 18.6g/dl)
in capillary blood were considered outliers, and 506 capillary blood measurements were used
for the final analysis (Fig 1). Normality was confirmed for the resulting datasets using the
Fig 1. Flowchart of study design. Excluded samples (dashed rectangles), total of Aptus (rounded rectangles) and HemoCue1
(rectangles) data points used for the statistical analyses are indicated. For venous blood, both Aptus and HemoCue1 samples
were taken during venipuncture and matched with the corresponding Medonic1measurement from the same sample tube.
For capillary blood, every Aptus data point was matched with the corresponding HemoCue1measurement.
https://doi.org/10.1371/journal.pone.0239931.g001
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Kolmogorov-Smirnov test. Paired t-tests and repeat measures ANOVA with the Greenhouse-
Geisser correction and Bonferroni post-hoc analysis were used for comparisons between
groups. Computation of Lin’s Concordance Correlation Coefficient (abbreviated rc) was con-
ducted using a macro S1 Macro. Lin’s coefficient analysis was conducted for the comparisons
with the automated analyzer in venous blood as it measures both association and agreement. It
represents a modification of Pearson’s correlation coefficient, in that it assesses not merely the
distance of data points to the line of best fit, but also how far this line deviates from the line of
perfect agreement, as represented by the 45-degree line through the origin. Lin’s coefficient
has a range of -1 to 1, with rc = 1 representing perfect agreement, in which all data points lie
on the 45-degree line. As points either depart from this line, or as the line of best fit departs
from the 45-degree line, the rc value diminishes [27, 28].
Results
Demographics
A total of 805 samples (190 venous blood and 615 capillary blood) were collected from 223
study participants enrolled in cohort 3 of the IHAT-GUT trial (Table 2). After excluding sam-
ples with erroneous measurements (see above) and data outliers, a total of 686 Aptus Hb mea-
surements were included in the final dataset (Fig 1).
Venous blood Hb concentration by Aptus and HemoCue1 compared to
the automated hematology analyzer
Each measurement included in this set of comparisons (Table 3) is from an individual child.
The mean Hb concentrations obtained by the Aptus (10.4±1.0 g/dl) and HemoCue1 (10.6
±0.9 g/dl) devices were not statistically different (Table 3, p = 0.15). The mean difference in Hb
between Aptus and HemoCue1Hb measurements in venous blood was -0.11 (95% CI: -0.23,
0.00) g/dl (Fig 2).
Table 2. Baseline characteristics of study participants.
Age at enrollment (months)
Mean (SD) 19.58 (7.26)
Median (IQR) 20 (11)
Range (min, max) 6, 35
Sex
Female n = 117
Male n = 106
Z–Scores
Mean Weight-for-Age (SD) -0.84 (0.83)
Mean Height-for-Age (SD) -0.69 (0.87)
Mean Weight-for-Height (SD) -0.77 (0.82)
Hb (g/dl) Medonic (n = 218)
Mean (SD) 9.14 (0.91)
Median (IQR) 9.15 (1.20)
Range (min, max) 6.9, 11.2
Ferritin (μg/l) (n = 218)
Mean (SD) 17.08 (21.99)
Median (IQR) 11.75 (14.03)
Range (min, max) 0.1, 247.5
https://doi.org/10.1371/journal.pone.0239931.t002
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Both PoCDs measured significantly greater Hb concentrations than the Hb value obtained
by the Medonic1 automated hematology analyzer (Table 3, p<0.0001 for both comparisons).
The mean difference between Hb concentration measured by Aptus vs Medonic1 was 0.69
(95% CI: 0.57, 0.81) g/dl and that of HemoCue1 vs Medonic1 was 0.81 (95% CI: 0.73, 0.88)
g/dl (Fig 2). In both cases more than 60% of measurements showed differences in Hb concen-
tration between -1 and 1 g/dl (Fig 2).
Bland-Altman plots for the Hb concentration comparisons in venous blood samples are
shown in Fig 3. There is very little bias between the two PoCDs for the measurement of Hb
concentration with mean difference of -0.11 (95% CI: -0.228, 0.00) g/dl (Fig 3A). The Aptus
measurements (Fig 3B) show slightly broader limits of agreement than the HemoCue1mea-
surements (Fig 3C) for the comparison with the Medonic1 automated hematology analyzer.
The biases for Aptus of 0.69 (95% CI: 0.571, 0.813) g/dl (Fig 3B) and for HemoCue1 of 0.81
(95% CI: 0.733, 0.879) g/dl (Fig 3C) compared to the Medonic1 are similar.
The Desirable Biological Variation Database specifications propose a total error allowable
(TEa) for Hb of ±4.19% from the true value as acceptable for a device measuring hemoglobin
[29]. Taking the Medonic1measurements as the true value, the Aptus measured 122 mea-
surements (68%) and the HemoCue1 159 measurements (88%) outside of this range.
Overall, if we consider the commonly used clinically meaningful difference in Hb concen-
trations of ± 1 g/dl (29), in the Aptus vs HemoCue1 comparisons, 83.9% of values fell within
this 1 g/dl threshold, for Aptus vs Medonic1 this was 63.3% of values and for HemoCue1 vs
Medonic1, it was 69.4% of values.
Lin’s coefficient analysis plots are shown in Fig 4. The correlation coefficient (rc) for the
comparison of Hb concentration determined by Aptus vs HemoCue1 was rc = 0.688 (95% CI:
0.604, 0.756), for Aptus vs Medonic1 rc = 0.548 (95% CI: 0.458, 0.627) and for HemoCue1
vs Medonic1 rc = 0.636 (95% CI: 0.571, 0.694). For all of these comparisons, there is a positive
correlation between methods but the agreement is sub-optimal. Data for the comparison of
hematocrit measurements in venous blood between Aptus and Medonic1 are shown in S1
Table and S1 and S2 Figs.
A ROC analysis was also conducted on the venous blood comparison. As there was only
one confirmed case of severe anemia and the median values across all devices were close to or
Table 3. Blood hemoglobin concentrations as determined by Aptus, HemoCue1, and Medonic1 in venous blood samples.
Aptus Hb (g/dl) HemoCue1Hb (g/dl) Medonic1Hb (g/dl)
Number of datapoints 180 183 183
Minimum 7.7 7.5 6.7
25% Percentile 9.7 10.1 9.1
Median 10.4 10.6 9.8
75% Percentile 11.0 11.2 10.4
Maximum 13.2 13.5 13.2
Mean 10.44 10.56 9.75
Std. Deviation 1.05 0.92 0.99
Std. Error of Mean 0.08 0.07 0.07
Lower 95% CI 10.29 10.43 9.61
Upper 95% CI 10.60 10.69 9.90
Number of results� 11 g/dl (non-anemic) 53 65 20
Three data outliers were removed for Aptus. PoCD measurements were conducted on blood drops taken from a venous blood sample before it was collected into the
EDTA blood tube for the Medonic1measurements.
https://doi.org/10.1371/journal.pone.0239931.t003
PLOS ONE Hemoglobin point-of-care testing in rural Gambia
PLOS ONE | https://doi.org/10.1371/journal.pone.0239931 October 1, 2020 9 / 21
Fig 2. Histograms of the differences in hemoglobin (Hb) concentration measured in venous blood samples.
Aptus-HemoCue1 (panel A) and Aptus-Medonic1 (panel B) comparisons, n = 180; HemoCue1-Medonic1 (panel
C), n = 183. The frequency of each difference is represented as a % of total measurements. For these comparisons, 151
(83.9%) of values in panel 1, 114 (63.3%) in panel 2 and 127 (69.4%) in panel 3 showed differences in Hb concentration
between -1 and 1 g/dl.
https://doi.org/10.1371/journal.pone.0239931.g002
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above the threshold for moderate anemia of 10 g/dl (Table 3), these were deemed unusable as
an outcome measure. Instead, absence of anemia (Hb� 11g/dl) was taken as a binary outcome
Fig 3. Bland-Altman comparison of the hemoglobin measurements performed in venous blood samples. Data
represents the difference versus the average Hb results between Aptus-HemoCue1 (panel A), Aptus-Medonic1
(panel B) and HemoCue1-Medonic1 (panel C). The solid lines represent the mean difference between the
measurements (bias), while the dotted lines indicate the 95% limits of agreement between methods.
https://doi.org/10.1371/journal.pone.0239931.g003
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Fig 4. Lin’s Concordance Correlation Coefficient graphs for venous Hb comparison. The dotted line represents the
45-degree line of perfect agreement through the origin, while the solid blue line is the line of best fit. As the Aptus-
HemoCue1 panel 1 (n = 180) and Aptus-Medonic1 panel 2 (n = 180) indicate, the Aptus data has a more
pronounced spread in both graphs. Furthermore, the line of best fit deviates significantly from the 45-degree line than
in the HemoCue1-Medonic1 comparison, indicating weaker agreement. Conversely, the spread of data and angle of
the line of best fit in the HemoCue1-Medonic1 comparison in panel 2 (n = 183) illustrate that agreement between
both PoCDs is stronger compared to the Aptus.
https://doi.org/10.1371/journal.pone.0239931.g004
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measure to compare PoCDs with the lab analyzer, using the reference standard outcome as the
true measure. As can be seen in Fig 5, HemoCue1 was superior, with an AUC of 0.933 (Std.
Error: 0.023, 95% CI: 0.878, 0.989) compared with the Aptus’ AUC of 0.799 (Std. Error: 0.06,
95% CI: 0.681, 0.916).
Hb concentration measured by two PoCDs, Aptus and HemoCue1, in
capillary blood
A total of 506 measurements from 223 children were included in this set of comparisons.
Mean Hb concentrations measured in capillary blood by Aptus (10.33±1.11g/dl) and Hemo-
Cue1 (10.01±1.07g/dl) were statistically different (Table 4, p<0.0001). The mean difference
between Aptus and HemoCue1Hb concentration was 0.32 (95% CI 0.22–0.42) g/dl (Table 4).
There were 170 out of 506 (33.6%) measurements where the difference between the two mea-
surements was above the ± 1g/dl clinically significant threshold.
Fig 5. ROC curve comparison of Aptus and HemoCue1. HemoCue1 (solid line) proved superior to Aptus (dashed line) in
accuracy of measuring non-anemia, with an AUC of 0.933 compared to 0.799, respectively.
https://doi.org/10.1371/journal.pone.0239931.g005
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The Bland-Altman plot for the comparison between the two PoCDs is shown in Fig 6.
There is no significant relationship between the bias and the average Hb result. The distance
between the limits of agreement (-1.91g/dl, 2.54g/dl) is comparatively wide at 4.45 g/dl.
Table 4. Blood hemoglobin concentrations as determined by Aptus and HemoCue1 in capillary blood samples.
Aptus Hb (g/dl) HemoCue1Hb (g/dl) Aptus-HemoCue1Hb difference (g/dl)
Number of datapoints 506 506 506
Minimum 6.4 7.3 -3.1
25% Percentile 9.5 9.2 -0.4
Median 10.4 10.0 0.3
75% Percentile 11 10.8 1.0
Maximum 13.6 13.4 4.5
Mean 10.33 10.01 0.32
Std. Deviation 1.11 1.07 1.13
Std. Error of Mean 0.05 0.05 0.05
Lower 95% CI 10.23 9.92 0.22
Upper 95% CI 10.43 10.11 0.42
Two data outliers for the Aptus were removed. Capillary blood was collected from the same finger prick but measurements were conducted in two independent blood
drops.
https://doi.org/10.1371/journal.pone.0239931.t004
Fig 6. Bland-Altman comparison of the hemoglobin measurements performed in capillary blood samples by Aptus and HemoCue1. Data represents the difference
(Aptus–HemoCue1) versus the average Hb results. The solid lines represent the mean difference between the measurements (bias), while the dotted lines indicate the
95% limits of agreement between methods.
https://doi.org/10.1371/journal.pone.0239931.g006
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Aptus device usage
The Aptus device proved easily portable and intuitive in use. The two Aptus devices used in
this study were sufficient to cover the maximum of 85 participants per day. However, as photo-
metric measurement with Aptus only commences after centrifugation has completed, the
time-to-result is significantly longer in Aptus than HemoCue1 (Table 1). This could be a
drawback in very high-throughput settings when there is not much turnaround time between
patients being screened. Additionally, the centrifugation process is sensitive to both significant
vibrations and spatial orientation, which led to instances in which a measurement was not ini-
tiated or aborted. This did not pose a major impediment to normal usage when the manufac-
turer’s recommendations were followed. Moreover, errors in sampling are only detected with
photometry, which in the majority of cases made it impossible to collect a second sample from
the same participant, as they had already been processed by the IHAT-GUT nurses and left the
clinic. Errors in capillary blood sampling most commonly occurred due to underfilling of the
cuvette. The manufacturer’s instructions recommend that the capillary blood should form a
dome shaped droplet of sufficient size before attempting to fill the cuvette. However, many
children were distressed by the fingerprick, making it difficult to produce a droplet and appro-
priately fill the Aptus cuvette with the resulting blood film formed on the finger. This would
probably be improved when collecting blood in adults, with more experienced users or
improved cuvettes. This is in contrast to the HemoCue1 cuvette, which draws blood on con-
tact in any position and the device does not indicate errors from under- or over-filling. Con-
trarily, when placing a drop of venous blood from the needle on a plastic surface, the most
common error with the Aptus was overfilling.
Adverse events
Besides the observation that blood drawing caused some discomfort to the children, the study
reported no adverse events related to blood collection (capillary or venous). Abnormal blood
results, i.e. severe anemia (Hb<7 g/dl) were identified in 0 samples with HemoCue1 and 3
samples with Aptus. As the Aptus comparison was ancillary to the IHAT-GUT study, its
results did not trigger a subsequent analysis for severe anemia by Medonic1 as would have
been the case if severe anemia was identified by HemoCue1. However, during this study
there was one identified severe anemia case with Medonic1measurements collected as part
of the outcome assessment timepoints. As per IHAT-GUT protocol this participant was dis-
continued from the IHAT-GUT supplementation and received standard treatment.
Discussion
The large impact and preventable nature of anemia warrant large scale screen-and-treat efforts,
and cost-efficient and accurate PoCDs are a crucial element in this. The Aptus represents a
new development by measuring Hb and HCT concentration. This study assessed the accuracy
and usability of the new Aptus PoCD and the well-established HemoCue1 301 PoCD against
the automated hematology analyzer Medonic1M-series, in an ancillary study to the IHAT--
GUT clinical trial set in a community setting in rural The Gambia [20]. To our knowledge,
this study is the first to test the accuracy of Aptus in a low-income rural setting in children.
Overall, both PoCDs showed similar levels of agreement with the laboratory analyzer, how-
ever Aptus showed slightly lower bias and wider limits of agreement than the HemoCue1.
Both PoCDs were shown to overestimate Hb concentration, as has been shown in previous
studies with HemoCue1 in children in similar settings [14, 30].
Venous blood measurements exhibited better agreement both between the PoCDs and with
the laboratory analyzer in comparison to the agreement observed between the PoCDs in
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capillary blood. This is in line with previous research that shows PoCD agreement to be inferior
in capillary sampling [7, 14, 30], which is unsurprising given the mixed venous/arterial nature
of capillary blood [31], within-subject variation between drops from the same finger prick [32]
and dependency on proper technique for consistency of results [33]. This is reflected in the
present study by wider limits of agreement in the Bland-Altman plots, the difference of which
far exceeds the clinically acceptable inaccuracy of ± 1g/dl. This indicates that the within-subject
variation of measurements is large and the methods are thus not unequivocal in a clinically rele-
vant manner. Furthermore, SD values were larger for the capillary samples despite the much
larger sample size than in the venous comparison, thereby also indicating more variability of
results. The method used to obtain a PoCD sample from the venous blood by placing a drop on
a surface first (gravity method), might be of influence here, as it was found to be more accurate
than collection from finger prick in a study on the HemoCue1 in Rwanda [30]. While this has
not been previously evaluated for Aptus, it could partly explain the superior results in venous
sampling for both PoCDs. However, whereas both devices are capable of measuring Hb in
venous blood, their principal function is to be used as a rapid test in capillary blood collected
from a fingerprick, particularly in low-resource field settings where PoCDs largely function as a
primary diagnostic tool. Therefore, although direct comparison between the PoCDs and the
laboratory analyzer from one venous sample clearly minimized biases, and is thus the most suit-
able method for comparing accuracy, this study also included the capillary blood comparison
between the two PoCDs as this better represents their intended use.
The overestimation of Hb concentration by both PoCDs could translate to underestimating
anemia rates when these devices are used as the only diagnosis tool. Averaging multiple capil-
lary measurements, either by using multiple cuvettes [34] or collecting multiple drops of blood
in a tube and sampling from it [32], have been proposed to eliminate variation and improve
accuracy. However, such measures require both more time and materials, thereby making
them less feasible in LMICs and high-throughput screenings in particular. Alternative non-
invasive devices have not yet been shown to be consistently reliable [6, 35, 36], so more
advanced PoCD capabilities—such as the MCHC measurement of the Aptus—would improve
the value of invasive procedures. This holds for low-resource settings in particular, where full
blood count analysis is often unavailable and PoCDs are the modus operandi.
Thus, usability and appropriateness to such settings are important considerations. Whereas
the HemoCue1 series has long been recommended as standard for field settings in low
resource areas due to its portability, cost and user-friendliness [14], its performance is not
without criticism as studies on it provide mixed results [7, 14, 15, 18, 30, 37–39]. Reasons for
this variability are thought to include, among others, climatological factors, handling and stor-
age of the cuvettes, and sampling technique [11, 15, 40]. Furthermore, the lack of a specified
working range for both altitude and humidity is suboptimal, as both have been shown to influ-
ence reliability [39, 40]. Regardless of these constraints, the usage of the HemoCue1 in this
study proved simple, rapid, and without noteworthy malfunctions.
To our knowledge, this is the first instance in which this Aptus model was tested in high-
throughput and low-resource community settings in children. Aptus is far smaller in dimen-
sion and lighter than the HemoCue1, making it more portable, and has validated wide ranges
of altitude, temperature and humidity. A major advantage of the Aptus is that it measures
MCHC and HCT directly. As MCHC has intrinsic diagnostic value, it would be beneficial to
have the option to display MCHC directly post-measurement. This is particularly relevant
since this study revealed poorer agreement in the HCT values than for the calculated Hb values
(Figs S2 and 4, respectively), which is interesting as the Aptus uses the gold standard microhe-
matocrit method of determining hematocrit by centrifugation [41] whereas the flow-cytome-
try based models like the Medonic1 calculate HCT. This suggests that the MCHC has a
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strong corrective influence in the Hb calculation, and is thus an important variable to show
the device’s accuracy. Future studies should investigate this further.
The usage proved intuitive and simple, yet some limitations apply specifically to these set-
tings, namely the longer duration of measurement and difficulty in handling the cuvettes. If
the intended use is high-throughput screenings in rural field clinics, then the comparatively
longer measurement time due to centrifugation may be a disadvantage in comparison to
HemoCue1. A further consideration is that the battery of the Aptus model used was not
replaceable and the lack of a consistent power supply for recharging batteries in this type of
setting could lead to issues with continuous usage.
Based on field experience and statistical analysis, the Aptus appears comparable in measure-
ment capabilities to the standard of the HemoCue1 given the limitations cited. It is stressed
that the Aptus results may have been confounded by not adhering strictly to the manufactur-
er’s specifications. This included the frequent inability to obtain a large dome-shaped blood
droplet in the young children, use of the thumb for finger pricking instead of the second or
third digit, and squeezing of the finger in order to procure a sufficient amount of blood from
the child. This blood sampling procedure is discouraged since the resulting expulsion of inter-
stitial fluid can skew the measurement [33]. However, as the HemoCue1 sample was taken
using the same technique, a resulting bias can be assumed to be present in both measurements.
As the HemoCue1 and Aptus samples were always taken from the second and third drop of
blood produced, respectively, this bias would be comparable within measurements per device,
while it is still possible that the composition between second and third drop may have varied
due to this technique. Furthermore, the larger number of error messages observed with Aptus
was related to the lower level of experience with this device than with HemoCue1, which we
note as a limitation. Furthermore, the Aptus was operated by only one user, which could have
introduced bias, whereas HemoCue1 sampling was conducted by one of the five study nurses
who all had been using the device for ten months prior to this study, through which possible
biases would have been balanced and sampling technique could have been superior due to
increased experience with the device.
Overall, to improve usability of Aptus in high throughput settings by a wide range of users,
experienced or inexperienced, we recommend improvements to both the cuvettes and the tim-
ing of the error messages in the device, and the incorporation of additional battery charging
capabilities. We note that the Aptus model used in this study is one of the first available com-
mercially and, as a result of this study and feedback from other users, has undergone further
development to improve its accuracy, software interface and cuvette handling.
Conclusion
This was the first study of the Aptus device in this type of setting and was intended to inform
further development in terms of performance before wider adoption in resource-poor rural
areas. Aptus and HemoCue1 showed similar accuracy and both overestimated Hb levels,
which could lead to an underestimation of anemia prevalence when used as a screening or
diagnostic tool. Aptus showed promise with its operation unimpaired by the field clinic’s con-
ditions, but operational limitations concerning duration of measurements may make it less
suitable for high-throughput screening. Importantly, the additional diagnostic value of mea-
suring MCHC may make Aptus a superior choice if the improvements highlighted in this
study are achieved. Since MCHC analysis was beyond the scope of this paper, future studies
should investigate this. By broadening the range of validated PoCDs available to users, we
hope that anemia diagnosis and screening programs improve coverage for the benefit of bil-
lions of people around the world.
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Supporting information
S1 Data.
(XLSX)
S1 Macro. SPSS macro for Lin’s Concordance Correlation Coefficient. Macro used in the
study to calculate the Lin’s coefficient in SPSS. Available from: https://gjyp.nl/marta/Lin.sps.
Date accessed: 23.04.2019.
(DOCX)
S1 Table. Comparison of hematocrit (HCT) measurements between Aptus and Medonic1.
Measurements in the Aptus were conducted in blood drops taken from a venous blood sample.
Al HCT values given as percentage. The mean difference between the methods is 5.11 (95% CI:
4.76, 5.45) %, which was statistically significant (p<0.0001).
(DOCX)
S1 Fig. Bland-Altman plot for hematocrit (HCT) measured in venous blood by Aptus and
Medonic1. Data represents the difference (Aptus–Medonic1) versus the average HCT
results. The solid lines represent the mean difference between the measurements (bias) is
5.1%, while the dotted lines indicate the 95% limits of agreement between methods of 0.5
(lower) and 9.71% (upper) limit.
(TIF)
S2 Fig. Lin’s Concordance Correlation Coefficient for hematocrit (HCT) measured in
venous blood by Aptus and Medonic1. The dotted line represents the 45-degree line of per-
fect agreement through the origin, while the solid blue line is the line of best fit. Lin’s coeffi-
cient is rc = 0.285, and there is significant divergence from the 45-degree line and spread
around the line of best fit (S2 Fig). It must be noted that the Aptus1 does not provide deci-
mals for HCT while the Medonic1 does. This explains the columnar nature of the data in
both plots, and negatively influences agreement due to an inherently lower accuracy of the
Aptus1’s output.
(TIF)
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